Overview
Investment Type
Venture Capital
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 13, 2020 | Need startup funding? Here are 75+ venture capital firms in the DMV region | If you’re located in New York City or the Silicon Valley, venture capital firms are abundant and well covered by the media — you can’t escape them. But entrepreneurs in the DMV region don’t need to go so far to find a firm that could propel... |
| Jan 30, 2011 | BioTime buys out Cell Targeting | Stem cell technology developer Cell Targeting Inc. sold its assets to BioTime Inc. (AMEX:BTX) in a deal worth about $2.3 million. BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s common stock, which was trading aroun... |
| Jan 28, 2011 | Regenerative medicine startup Cell Targeting sold to BioTime | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| Sep 28, 2009 | Cell Targeting hopes to bring purpose to stem cell therapy | Promoted Clinical Care Capacity Planning Learn how to manage clinical care capacity more efficiently during uncertain times. SAP Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermin... |
| Aug 18, 2009 | Video: 3 stem cell businesses at MSC2009 | CLEVELAND, Ohio —MSC2009, the regenerative medicine and adult stem cell therapy conference, on Monday started a three-day gathering that features a largely academic audience from as far away as Brazil, Iran and Russia discussing innovations... |
| Cell Targeting hopes to bring purpose to stem cell therapy | CLEVELAND, Ohio –Â Joseph Wagner sees most cell-therapy companies offering little more than a bag of cells. His company will give the bag a little direction. Cell Targeting is developing technology that can point stem cell therapies to spec... | |
| Regenerative medicine startup Cell Targeting sold to BioTime | Stem cell technology developer Cell Targeting has sold its assets to BioTime (AMEX:BTX) in a deal worth about $2.3 million. BioTime will pay $250,000 in cash as well as 262,000 shares of BioTime’s common stock, which was trading around $7.7... |
Reviews 0
FAQ about Toucan Capital
What has the press written about Toucan Capital?
Parsers VC has collected 8 articles mentioning Toucan Capital, among them “Need startup funding? Here are 75+ venture capital firms in the DMV region” (Oct 13, 2020) and “BioTime buys out Cell Targeting” (Jan 30, 2011).
Is Toucan Capital still active?
Toucan Capital is probably closed: its latest activity on Parsers VC dates from Oct 16, 2020.